SynAct Pharma AB (OSTO:SYNACT) Total Liabilities : kr61.06 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB Total Liabilities?

SynAct Pharma AB's Total Liabilities for the quarter that ended in Mar. 2024 was kr61.06 Mil.

SynAct Pharma AB's quarterly Total Liabilities declined from Sep. 2023 (kr66.01 Mil) to Dec. 2023 (kr51.83 Mil) but then increased from Dec. 2023 (kr51.83 Mil) to Mar. 2024 (kr61.06 Mil).

SynAct Pharma AB's annual Total Liabilities declined from Dec. 2021 (kr17.50 Mil) to Dec. 2022 (kr16.08 Mil) but then increased from Dec. 2022 (kr16.08 Mil) to Dec. 2023 (kr51.83 Mil).

SynAct Pharma AB Total Liabilities Historical Data

The historical data trend for SynAct Pharma AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB Total Liabilities Chart

SynAct Pharma AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

13.73

5.73

17.50

16.08

51.83

SynAct Pharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															52.24	56.97	66.01	51.83	61.06

SynAct Pharma AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

SynAct Pharma AB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	24.938	+	(0.058	+	26.836
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	51.83

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	228.018	-	176.186
	=	51.83

SynAct Pharma AB's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	27.188	+	(0.024	+	33.848
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	61.06

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	213.354	-	152.294
	=	61.06

SynAct Pharma AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of SynAct Pharma AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

SynAct Pharma AB (OSTO:SYNACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

8F8:Germany

Address

Sheelevagen 2, Lund, SWE, 223 81

Website

https://www.synactpharma.se

SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines